Form 51-102F3
Material Change Report

1. Name and Address of Company

Resverlogix Corp.
300, 4820 Richard Road SW
Calgary, AB T3E 6L1

2. Date of Material Change

June 9, 2017

3. News Release

June 9, 2017 via CNW Group

4. Summary of Material Change

Resverlogix Corp. (“Resverlogix” or the “Company”) announced that Bloom Burton Securities Inc. carried out an overnight marketed equity offering and confirmed up to $10 million in demand for equity units of the Company, representing up to 5,555,556 units at a price of $1.80, with each unit consisting of one common share and one common share purchase warrant exercisable at a price of $2.05 per underlying common share for a period of four years from closing of the offering.

5. Full Description of Material Change

Resverlogix announced that Bloom Burton Securities Inc. carried out an overnight marketed equity offering and confirmed up to $10 million in demand for equity units of the Company, representing up to 5,555,556 units at a price of $1.80. Each unit consists of one common share and one common share purchase warrant. Each warrant is exercisable at a price of $2.05 per underlying common share for a period of four years from the closing of the offering. The offering is to be effected in each of the Canadian provinces, other than Québec, by way of a prospectus supplement to Resverlogix’s base shelf prospectus dated October 1, 2015. Prior to the offering, Resverlogix has 105,701,543 common shares issued and outstanding.

The net proceeds of the offering will be used to fund research and development activities, including but not limited to, trial activities related to Phase 3 BETonMACE trial, Phase 2a kidney dialysis trial and Fabry disease trial, general and administrative expenses, working capital needs and other general corporate purposes.

The transaction is scheduled to close on or about June 20, 2017, subject to satisfaction of customary closing conditions, including the receipt of all necessary regulatory and stock exchange approvals.

Forward-Looking Information

This material change report may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this material change report includes forward looking information relating to the completion of the offering, the use of net proceeds from the offering, and the potential role of apabetalone in the treatment of CVD, DM, chronic kidney disease, end-stage renal disease treated with hemodialysis, Alzheimer's disease, Fabry disease, and Orphan diseases. Our actual results, *events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this material change report are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.*

6. Reliance of subsection 7.1(2) of National Instrument 51-102

N/A

7. Omitted Information

N/A

8. Executive Officer

Donald J. McCaffrey, President and CEO
Telephone: (403) 254-9252

9. Date of Report

June 12, 2017